
    
      Patients will received Imatinib at a dose of 400mg daily. Tolerability and quality of life
      will be assessed Secondary objectives are : to evaluate the survival without progression, the
      survival without event, the overall survival, the hematologic, cytogenetic and molecular
      responses at various check points.

      Duration of responses and failure to respond will be evaluated.
    
  